KDR and hepatocellular carcinoma: In HCC, anti-angiogenic therapies commonly involve large-molecule monoclonal antibodies targeting VEGF or vascular endothelial growth factor receptor (VEGFR), as well as small molecule tyrosine kinase inhibitors (TKIs) targeting multiple receptors.